We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Nano-tech Diagnostic Can Indicate Cancer or Thrombotic Risk in One Drop of Blood

Nano-tech Diagnostic Can Indicate Cancer or Thrombotic Risk in One Drop of Blood content piece image
Credit: Pixabay
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

A team of international researchers led by Professor Martin Hegner, Investigator in CRANN and Trinity’s School of Physics, have developed an automated diagnostic platform that can quantify bleeding – and thrombotic risks – in a single drop of blood, within seconds.

The researchers exploited micro-resonators for real-time measurements of the evolving strength of the blood plasma clot. Along with the clinically measured clotting time, other insightful parameters, from specific factor deficiency to global coagulation parameters (used to assess fibrinolysis), can also be extracted. These technical developments introduce a miniaturised global haemostasis assay with the capability of fine-tuning factor replacement – or anti-coagulation therapies.

In collaboration with the multinational, Hoffman-la-Roche, the researchers report a novel strategy for quick, reliable and quantitative diagnostics of expression patterns of non-coding short RNA in blood plasma or cell cultures. They directly detect label-free specific miRNA biomarkers relevant to cancer and adverse drug effects in blood-based samples.

Professor Hegner’s work focuses on the development of innovative nanotechnological automated diagnostic platforms that underpin next-generation medical devices. The collaboration with the multinational Hoffman-la-Roche, a world leader in in-vitro diagnostics, enabled this scientific study and provides the possibility to further miniaturise this device for portable point-of-care testing for the market and society.

Professor Hegner said: “This has significant implications for a non-invasive, rapid and personalised diagnosis using nanomechanical sensors. We believe that the comprehensive direct diagnostic approach to analyse blood haemostasis and the abundance of specific miRNA in cells and serum has a significant impact on various areas including but not limited to cancer diagnostics or drug-adverse effects where such markers are excreted into the blood stream.”

This article has been republished from materials provided by Trinity College Dublin. Note: material may have been edited for length and content. For further information, please contact the cited source.


Duffy, J., Padovani, F., Brunetti, G., Noy, P., Certa, U., & Hegner, M. (2018). Towards personalised rapid label free miRNA detection for cancer and liver injury diagnostics in cell lysates and blood based samples. Nanoscale, 10(26), 12797-12804. doi: 10.1039/c8nr03604g